Back to search

Peptide record

TPDB07267

Antibacterial Antifungal Antiviral Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07267
Antibacterial Antifungal Antiviral Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia Antifungipept CAFPdb DRAVP 2.0 HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Antifungal, Antiviral, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FVPWFSKFLGRIL
Physicochemical Analysis
C83H120N18O15
ANDCEQHMTY
F
1609.98
11.49
2
0
8
+2
-4.21
0.969
112.31
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
5500
341.62
1
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
1
I
2
L
1
K
0
M
3
F
1
P
1
S
0
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 2 K: 1 M: 0 F: 3 P: 1 S: 1 T: 0 W: 1 Y: 0 V: 1
Chemical Descriptors
13
C83H120N18O15
1609.98
11.49
+2
-4.21
0.969
Evidence Records 8 records
Evidence 1 Activity

Activity

% Hemolysis
Hemolysis
4 3 3 2 1 2.66 3.99 3.85 %
[Ref.28863356] 21±4% hemolysis at 50µM, 7±3% hemolysis at 25µM, 6±3% hemolysis at 12.5µM, 3±2% hemolysis at 6.25µM, 1±1% hemolysis at 3.125µM against human red blood cells.##20.63 ± 2.66% cytotoxic effect at 12.5µM, 57.52 ± 3.99% cytotoxic effect at 25µM, 91.58 ± 3.85% cytotoxic effect at 50 µM on HaCaT cells.

Target

human red blood cells

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Eur J Med Chem. 2017 Oct 20 139:750-761.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 2 Activity

Activity

92% Hemolysis
Toxicity
24 µM
Hemolytic Cytotoxic
92% Hemolysis | 24 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-activity relationship, conformational and biological studies of temporin L analogues. | J Med Chem | 2011
Evidence 3 Activity

Activity

42% Hemolysis
Toxicity
12 µM
Hemolytic Cytotoxic
42% Hemolysis | 12 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-activity relationship, conformational and biological studies of temporin L analogues. | J Med Chem | 2011
Evidence 4 Activity

Activity

10% Hemolysis
Toxicity
6 µM
Hemolytic Cytotoxic
10% Hemolysis | 6 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-activity relationship, conformational and biological studies of temporin L analogues. | J Med Chem | 2011
Evidence 5 Activity

Activity

6% Hemolysis
Toxicity
3 µM
Hemolytic Cytotoxic
6% Hemolysis | 3 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-activity relationship, conformational and biological studies of temporin L analogues. | J Med Chem | 2011
Evidence 6 Activity

Activity

5% Hemolysis
Toxicity
1.5 µM
Hemolytic Cytotoxic
5% Hemolysis | 1.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-activity relationship, conformational and biological studies of temporin L analogues. | J Med Chem | 2011
Evidence 7 Activity

Activity

% Hemolysis
Toxicity
4 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.28863356] 21±4% hemolysis at 50µM, 7±3% hemolysis at 25µM, 6±3% hemolysis at 12.5µM, 3±2% hemolysis at 6.25µM, 1±1% hemolysis at 3.125µM against human red blood cells.##20.63 ± 2.66% cytotoxic effect at 12.5µM, 57.52 ± 3.99% cytotoxic effect at 25µM, 91.58 ± 3.85% cytotoxic effect at 50 µM on HaCaT cells. | Cytotoxicity: [Ref.28863356] The cytotoxic effects of the peptide are 20.63±2.66%, 57.52±3.99% and 91.58±3.85% at 12.5, 25 and 50 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Eur J Med Chem. 2017 Oct 20 139:750-761.
Evidence 8 Hemolysis

Activity

4 3 3 2 1 2.66 3.99 3.85 %
% Hemolysis
[Ref.28863356] 21±4% hemolysis at 50µM, 7±3% hemolysis at 25µM, 6±3% hemolysis at 12.5µM, 3±2% hemolysis at 6.25µM, 1±1% hemolysis at 3.125µM against human red blood cells.##20.63 ± 2.66% cytotoxic effect at 12.5µM, 57.52 ± 3.99% cytotoxic effect at 25µM, 91.58 ± 3.85% cytotoxic effect at 50 µM on HaCaT cells.
Hemolysis

Target

human red blood cells

Source & Reference

HemoPI PD_Hemolysis
Eur J Med Chem. 2017 Oct 20 139:750-761.
DRAMP4
PD_Hemolysis